<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05017194</url>
  </required_header>
  <id_info>
    <org_study_id>EMODEP_PEMBA</org_study_id>
    <nct_id>NCT05017194</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm</brief_title>
  <acronym>EMODEP_PEMBA</acronym>
  <official_title>Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm: Randomized Two Stages Phase II Seamless Adaptive Controlled Single-blind Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Keiser</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Public Health Laboratory Ivo de Carneri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Tropical &amp; Public Health Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale of the study is to provide evidence on the efficacy and safety of Emodepside in&#xD;
      adults infected with Trichuris trichiura and hookworm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2021</start_date>
  <completion_date type="Anticipated">October 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate (CR) of emodepside against Trichuris trichiura</measure>
    <time_frame>In the week between 14 and 21 days post-treatment</time_frame>
    <description>CR will be calculated as the percentage of Trichuris trichiura egg-positive participants at baseline who become egg-negative after treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cure rate (CR) of emodepside against hookworm</measure>
    <time_frame>In the week between 14 and 21 days post-treatment</time_frame>
    <description>CR will be calculated as the percentage of hookworm egg-positive participants at baseline who become egg-negative after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Egg Reduction Rate (ERR) of the emodepside against Trichuris trichiura and hookworm.</measure>
    <time_frame>In the week between 14 and 21 days post-treatment</time_frame>
    <description>Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the &quot;outcome measure&quot; entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR against Ascaris lumbricoides</measure>
    <time_frame>In the week between 14 and 21 days post-treatment</time_frame>
    <description>CR will be calculated as the percentage of Ascaris lumbricoides egg-positive participants at baseline who become egg-negative after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ERR against Ascaris lumbricoides</measure>
    <time_frame>In the week between 14 and 21 days post-treatment</time_frame>
    <description>Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the &quot;outcome measure&quot; entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Trichuris Trichiura; Infection</condition>
  <condition>Hookworm Infections</condition>
  <arm_group>
    <arm_group_label>Emodepside 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Emodepside 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Emodepside 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Emodepside 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Emodepside 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Emodepside 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Albendazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emodepside</intervention_name>
    <description>Treatment with ascending doses of emodepside (from 5 mg to 30 mg) or albendazole (400 mg) or placebo.</description>
    <arm_group_label>Albendazole</arm_group_label>
    <arm_group_label>Emodepside 10 mg</arm_group_label>
    <arm_group_label>Emodepside 15 mg</arm_group_label>
    <arm_group_label>Emodepside 20 mg</arm_group_label>
    <arm_group_label>Emodepside 25 mg</arm_group_label>
    <arm_group_label>Emodepside 30 mg</arm_group_label>
    <arm_group_label>Emodepside 5 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adults aged between 18 and 45 years&#xD;
&#xD;
          -  Written and signed informed consent&#xD;
&#xD;
          -  Examined by a study physician before treatment&#xD;
&#xD;
          -  Provided two stool samples at baseline&#xD;
&#xD;
          -  Trichuris trichiura and hookworm EPG &gt; 48 and at least two Kato-Katz thick smears&#xD;
             slides with more than one Trichuris trichiura and hookworm eggs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating and/or planning to become pregnant within three months after&#xD;
             drug treatment&#xD;
&#xD;
          -  Type 1 and/or 2 diabetes&#xD;
&#xD;
          -  Psychiatric disorders&#xD;
&#xD;
          -  History of ophthalmological conditions&#xD;
&#xD;
          -  Presence or history of major systemic or chronic illnesses, as assessed by a medical&#xD;
             doctor, during initial clinical assessment&#xD;
&#xD;
          -  Suffers from severe anaemia (Hb &lt; 80 g/l)&#xD;
&#xD;
          -  Received anthelminthic treatment within past four weeks&#xD;
&#xD;
          -  Attending other clinical trials during the study&#xD;
&#xD;
          -  Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that&#xD;
             are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin&#xD;
&#xD;
          -  Received strong P-gp inhibitors as well as concomitant treatments that are relevant&#xD;
             substrates for P-gp such as clotrimazole and ritonavir&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Keiser, PhD</last_name>
    <phone>+41 61 284 8218</phone>
    <email>jennifer.keiser@swisstph.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emmanuel Mrimi, MSc</last_name>
    <phone>+41 77 945 5073</phone>
    <email>emmanuel.mrimi@swisstph.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Public Health Laboratory - Ivo de Carneri</name>
      <address>
        <city>Chake Chake</city>
        <zip>122</zip>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Said Ali, MSc</last_name>
      <phone>+255 24 245 2003</phone>
      <email>saidmali2003@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Emmanuel C Mrimi, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie B Welsche, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Karpstein, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Said Ali, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Tropical &amp; Public Health Institute</investigator_affiliation>
    <investigator_full_name>Jennifer Keiser</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Emodepside</keyword>
  <keyword>Trichuris trichiura</keyword>
  <keyword>Hookworm</keyword>
  <keyword>Soil-transmitted helminths</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Dose selection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hookworm Infections</mesh_term>
    <mesh_term>Ancylostomiasis</mesh_term>
    <mesh_term>Trichuriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emodepside</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

